Download PDF
Klin Monbl Augenheilkd 2013; 230(2): 127-132
DOI: 10.1055/s-0032-1327946
Übersicht
Georg Thieme Verlag KG Stuttgart · New York

Wirkmechanismen, klinisches Profil und Stellenwert von Prostaglandin- und Prostamid-Analoga in der antiglaukomatösen Therapie

Mechanisms, Clinical Profile and Role of Prostaglandin and Prostamide Analogues in Antiglaucomatous Therapy
A. Yu
1   Augenklinik, Ludwig-Maximilians-Universität, München
,
U. Welge-Lüßen
2   Augenklinik, Universität Erlangen-Nürnberg, Erlangen
› Author Affiliations
Further Information

Publication History

eingereicht 29 August 2012

akzeptiert 17 October 2012

Publication Date:
20 January 2013 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Prostaglandin- und Prostamid-Analoga gehören zu einer neueren Gruppe von Substanzen, die in den 1990er-Jahren auf den Markt kamen. Sie haben die antiglaukomatöse Therapie durch ihre einfache Dosierung und ihren geringeren Nebenwirkungen revolutioniert. Heute sind Prostaglandin- und Prostamid-Analoga als First-Line-Therapie bei Patienten mit primären Offenwinkelglaukom und okulärer Hypertension zugelassen. Sie senken den intraokularen Druck primär über die Erhöhung des uveoskleralen Abflusses. Allerdings zeigen neuere Untersuchungen, dass sie auch einen Einfluss auf die trabekuläre Abflussfazilität haben und damit die konventionellen Abflusswege verbessern können. Prostaglandin- und Prostamid-Analoga zeichnen sich durch eine hohe Effizienz in der intraokularen Drucksenkung aus, die der von den anderen antiglaukomatösen Substanzgruppen überlegen ist. Sie scheinen insbesondere durch die primäre Abflussverbesserung eine gute Kontrolle von Druckfluktuationen über 24 Stunden zu haben. Des Weiteren haben sie geringere systemische Nebenwirkungen als β-Blocker. Ihr Einsatz ist allerdings mit höheren Kosten verbunden. Im Fall von unerwünschten Ereignissen gehen sie vor allem mit okulären Symptomen einher. Somit haben Prostaglandin- und Prostamid-Analoga aufgrund ihres guten klinischen Profils einen festen Stellenwert als primäre oder ergänzende Therapie in der Behandlung von Glaukomerkrankungen.

Abstract

Prostaglandin and prostamide analogues belong to a new substance group which came into the market in the 1990s. They have revolutionised antiglaucomatous therapy by their once-daily dosing regimen and fewer side effects. Today, prostaglandin and prostamide analogues are approved as first-line therapy for patients with primary open-angle glaucoma and ocular hypertension. They lower the intraocular pressure primarily by increasing the uveoscleral outflow. Recent investigations have shown that they also improve the trabecular outflow facility and thus the conventional outflow pathways. Prostaglandin and prostamide analogues are highly efficient in lowering the intraocular pressure, for which they are superior to other antiglaucomatous substance groups. In particular, they appear to have a good control of 24-hour intraocular pressure fluctuations by primarily improving the outflow pathways. Furthermore, they have less systemic side effects than β-blockers. However, their use is often associated with higher costs. In case of undesirable events, they mostly present with ocular symptoms. Based on their good clinical profile, prostaglandin and prostamide analogues play an important role in the primary and additive therapy for glaucoma.

Schlüsselwörter

Glaukom - intraokularer Druck - Prostaglandinanaloga

Key words

glaucoma - intraocular pressure - prostaglandin analogues
 

  • Literatur

  • 1 Camras CB, Bito LZ. Reduction of intraocular pressure in normal and glaucomatous primate (Aotus trivirgatus) eyes by topically applied prostaglandin F2α . Curr Eye Res 1981; 1: 205-209
    CrossrefPubMedGoogle Scholar
  • 2 Alm A. Prostaglandin derivates as ocular hypotensive agents. Prog Retin Eye Res 1998; 17: 291-312
    CrossrefPubMedGoogle Scholar
  • 3 Giuffré G. The effects of prostaglandin F2α in the human eye. Graefeʼs Arch Clin Exp Ophthalmol 1985; 222: 139-141
    PubMedGoogle Scholar
  • 4 Ishida N, Odani-Kawabata N, Shimazaki A et al. Prostanoids in the therapy of glaucoma. Cardiovasc Drug Rev 2006; 241: 1-10
    PubMedGoogle Scholar
  • 5 Crowston JG, Lindsey JD, Morris CA et al. Effect of bimatoprost on intraocular pressure in prostaglandin FP receptor knockout mice. Invest Ophthalmol Vis Sci 2005; 46: 4571-4577
    CrossrefPubMedGoogle Scholar
  • 6 Ota T, Aihara M, Narumiya S et al. The effects of prostaglandin analogues on IOP in prostanoid FP-receptor-deficient mice. Invest Ophthalmol Vis Sci 2005; 46: 4159-4163
    CrossrefPubMedGoogle Scholar
  • 7 Camras CB, Toris CB, Sjoquist B et al. Detection of the free acid of bimatoprost in aqueous humor samples from human eyes treated with bimatoprost before cataract surgery. Ophthalmology 2004; 111: 2193-2198
    CrossrefPubMedGoogle Scholar
  • 8 Costagliola C, dellʼOmo R, Romano MR et al. Pharmacotherapy of intraocular pressure – part II. Carbonic anhydrase inhibitors, prostaglandin analogues and prostamides. Expert Opin Pharmacother 2009; 10: 2859-2870
    CrossrefPubMedGoogle Scholar
  • 9 Ooi YH, Oh DJ, Rhee DJ. Effect of bimatoprost, latanoprost, and unoprostone on matrix metalloproteinases and their inhibitors in human ciliary body smooth muscle cells. Invest Ophthalmol Vis Sci 2009; 50: 5259-5265
    CrossrefPubMedGoogle Scholar
  • 10 Richter M, Krauss AH, Woodward DF et al. Morphological changes in the anterior eye segment after long-term treatment with different receptor selective prostaglandin agonists and a prostamide. Invest Ophthalmol Vis Sci 2003; 44: 4419-4426
    CrossrefPubMedGoogle Scholar
  • 11 Kim JW, Lindsey JD, Wang N et al. Increased human scleral permeability with prostaglandin exposure. Invest Ophthalmol Vis Sci 2001; 427: 1514-1521
    PubMedGoogle Scholar
  • 12 Oh DJ, Martin JL, Williams AJ et al. Effect of latanoprost on the expression of matrix metalloproteinases and their tissue inhibitors in human trabecular meshwork cells. Invest Ophthalmol Vis Sci 2006; 47: 3887-3895
    CrossrefPubMedGoogle Scholar
  • 13 Bahler CK, Howell KG, Hann CR et al. Prostaglandins increase trabecular meshwork outflow facility in cultured human anterior segments. Am J Ophthalmol 2008; 145: 114-119
    CrossrefPubMedGoogle Scholar
  • 14 Thieme H, Schimmat C, Münzer G et al. Endothelin antagonism: effects of FP receptor agonists prostaglandin F2alpha and fluprostenol on trabecular meshwork contractility. Invest Ophthalmol Vis Sci 2006; 47: 938-945
    CrossrefPubMedGoogle Scholar
  • 15 van der Valk R, Webers CA, Schouten JS et al. Intraocular pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trials. Ophthalmology 2005; 112: 1177-1185
    CrossrefPubMedGoogle Scholar
  • 16 Bean GW, Camras CB. Commercially available prostaglandin analogs for the reduction of intraocular pressure: similarities and differences. Surv Ophthalmol 2008; 53: S69-S84
    CrossrefPubMedGoogle Scholar
  • 17 Lindén C, Alm A. Latanoprost twice daily is less effective than once daily : indication of receptor subsensitivity?. Curr Eye Res 1998; 17: 567-572
    CrossrefPubMedGoogle Scholar
  • 18 Alm A, Camras CB, Watson PG. Phase III latanoprost studies in Scandinavia, the United Kingdom and the United States. Surv Ophthalmol 1997; 41: S105-S110
    CrossrefPubMedGoogle Scholar
  • 19 Alm A, Stjernschantz J. Effects on intraocular pressure and side effects of 0.005 % latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group. Ophthalmology 1995; 102: 1743-1752
    PubMedGoogle Scholar
  • 20 Brubaker RF. Targeting outflow facility in glaucoma management. Surv Ophthalmol 2003; 48: 17-20
    CrossrefPubMedGoogle Scholar
  • 21 Rushton A. Cyclic AMP and intraocular pressure. Lancet 1983; 2: 737
    PubMedGoogle Scholar
  • 22 Graham SL, Drance SM, Wijsman K et al. Ambulatory blood pressure monitoring in glaucoma: the nocturnal dip. Ophthalmology 1995; 102: 61-69
    PubMedGoogle Scholar
  • 23 Racz P, Ruzsonyi MR, Nagy ZT et al. Around-the-clock (circadian) intraocular pressure reduction with once-daily application of 0.005 % latanoprost by itself or in combination with timolol. Arch Ophthalmol 1996; 114: 268-273
    CrossrefPubMedGoogle Scholar
  • 24 Orzalesi N, Rossetti L, Invernizzi T et al. Effect of timolol, latanoprost, and dorzolamide on circadian IOP in glaucoma or ocular hypertension. Invest Ophthalmol Vis Sci 2000; 41: 2566-2573
    PubMedGoogle Scholar
  • 25 Netland PA, Landry T, Sullivan EK et al. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol 2001; 132: 472-484
    CrossrefPubMedGoogle Scholar
  • 26 Stewart WC, Konstas AG, Nelson LA et al. Meta-analysis of 24-hour intraocular pressure studies evaluating the efficacy of glaucoma medicines. Ophthalmology 2008; 115: 1117-1122
    CrossrefPubMedGoogle Scholar
  • 27 Costagliola C, Del Prete A, Verolino M et al. Effect of 0.005 % latanoprost once daily on intraocular pressure in glaucomatous patients not adequately controlled by beta-blockers twice daily: a 3-year follow-up. Experience and incidence of side-effects in a prospective study on 76 patients. Graefes Arch Clin Exp Ophthalmol 2002; 240: 379-386
    CrossrefPubMedGoogle Scholar
  • 28 Susanna Jr R, Chew P, Kitazawa Y. Current status of prostaglandin therapy: latanoprost and unoprostone. Surv Ophthalmol 2002; 47: S97-S104
    CrossrefPubMedGoogle Scholar
  • 29 Watson P, Stjernschantz J. the Latanoprost Study Group. A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. Ophthalmology 1996; 103: 126-137
    PubMedGoogle Scholar
  • 30 Sakurai M, Higashide T, Takahashi M et al. Association between genetic polymorphisms of the prostaglandin f2α receptor gene and response to latanoprost. Ophthalmology 2007; 114: 1039-1045
    CrossrefPubMedGoogle Scholar
  • 31 Williams RD. Efficacy of bimatoprost in glaucoma and ocular hypertension unresponsive to latanoprost. Adv Ther 2002; 19: 275-281
    CrossrefPubMedGoogle Scholar
  • 32 Gandolfi SA, Cimino L. Effect of bimatoprost on patients with primary open-angle glaucoma on ocular hypertension who are nonresponders to latanoprost. Ophthalmology 2003; 110: 609-614
    CrossrefPubMedGoogle Scholar
  • 33 Susanna Jr. R, Nicolela MT, Oga E. Additive effect of latanoprost to the combination of timolol and dorzolamide. J Glaucoma 2000; 9: 183-186
    CrossrefPubMedGoogle Scholar
  • 34 Diestelhorst M. The additive intraocular pressure-lowering effect of latanoprost 0.005 % daily once and pilocarpine 2 % t.i.d. in patients with open-angle glaucoma or ocular hypertension. A 6-month, randomized, multicenter study. German Latanoprost Study Group. Graefes Arch Clin Exp Ophthalmol 2000; 238: 433-439
    CrossrefPubMedGoogle Scholar
  • 35 Stewart WC, Sharpe ED, Day DG et al. Comparison of the efficacy and safety of latanoprost 0.005 % compared to brimonidine 0.2 % or dorzolamide 2 % when added to a topical beta-adrenergic blocker in patients with primary open-angle glaucoma or ocular hypertension. J Ocul Pharmacol Ther 2000; 16: 251-259
    CrossrefPubMedGoogle Scholar
  • 36 OʼConnor DJ, Martone JF, Mead A. Additive intraocular pressure lowering effect of various medications with latanoprost. Am J Ophthalmol 2002; 133: 836-837
    CrossrefPubMedGoogle Scholar
  • 37 Feldman RM, Tanna AP, Gross RL et al. Comparison of the ocular hypotensive efficacy of adjunctive brimonidine 0.15 % or brinzolamide 1 % in combination with travoprost 0.004 %. Ophthalmology 2007; 114: 1248-1254
    CrossrefPubMedGoogle Scholar
  • 38 Tabet R, Stewart WC, Feldman R et al. A review of additivity to prostaglandin analogs: fixed and unfixed combinations. Surv Ophthalmol 2008; 53: S85-S92
    CrossrefPubMedGoogle Scholar
  • 39 Kent AR, Vroman DT, Thomas TJ et al. Interaction of pilocarpine with latanoprost in patients with glaucoma and ocular hypertension. J Glaucoma 1999; 8: 257-262
    PubMedGoogle Scholar
  • 40 McKibbin M, Menage MJ. The effect of once-daily latanoprost on intraocular pressure and pulsatile ocular blood flow in normal tension glaucoma. Eye 1999; 13: 31-34
    CrossrefPubMedGoogle Scholar
  • 41 Hung PT, Hsieh JW, Chen YF et al. Efficacy of latanoprost as an adjunct to medical therapy for residual angle-closure glaucoma after iridectomy. J Ocul Pharmacol Ther 2000; 16: 43-47
    CrossrefPubMedGoogle Scholar
  • 42 Scherer WJ, Hauber FA. Effect of latanoprost on intraocular pressure in steroid-induced glaucoma. J Glaucoma 2000; 9: 179-182
    CrossrefPubMedGoogle Scholar
  • 43 Mastropasqua L, Carpineto P, Ciancaglini M et al. A 12-month, randomized, double-masked study comparing latanoprost with timolol in pigmentary glaucoma. Ophthalmology 1999; 106: 550-555
    CrossrefPubMedGoogle Scholar
  • 44 Horsley MB, Chen TC. The use of prostaglandin analogs in the uveitic patient. Semin Ophthalmol 2011; 26: 285-289
    CrossrefPubMedGoogle Scholar
  • 45 Alvarado JA, Iguchi R, Martinez J et al. Similar effects of selective laser trabeculoplasty and prostaglandin analogs on the permeability of cultured Schlemm canal cells. Am J Ophthalmol 2010; 150: 254-264
    CrossrefPubMedGoogle Scholar
  • 46 Alvarado JA, Iguchi R, Juster R et al. From the bedside to the bench and back again: predicting and improving the outcomes of SLT glaucoma therapy. Trans Am Ophthalmol Soc 2009; 107: 167-181
    PubMedGoogle Scholar
  • 47 Scherer WJ. Effect of topical prostaglandin analog use on outcome following selective laser trabeculoplasty. J Ocul Pharmacol Ther 2007; 23: 503-512
    CrossrefPubMedGoogle Scholar
  • 48 Singh D, Coote MA, OʼHare F et al. Topical prostaglandin analogues do not affect selective laser trabeculoplasty outcomes. Eye 2009; 23: 2194-2199
    CrossrefPubMedGoogle Scholar
  • 49 Ayala M, Chen E. The influence of topical prostaglandin analogues in inflammation after selective laser trabeculoplasty treatment. J Ocul Pharmacol Ther 2012; 28: 118-122
    CrossrefPubMedGoogle Scholar
  • 50 Ishii K, Tomidokoro A, Nagahara M et al. Effects of topical latanoprost on optic nerve head circulation in rabbits, monkeys, and humans. Invest Ophthalmol Vis Sci 2001; 42: 2957-2963
    PubMedGoogle Scholar
  • 51 Alm A, Grierson I, Shields MB. Side effects associated with prostaglandin analog therapy. Surv Ophthalmol 2008; 53: S93-S105
    CrossrefPubMedGoogle Scholar
  • 52 Honrubia F, García-Sánchez J, Polo V et al. Conjunctival hyperaemia with the use of latanoprost versus other prostaglandin analogues in patients with ocular hypertension or glaucoma: a meta-analysis of randomised clinical trials. Br J Ophthalmol 2009; 93: 316-321
    CrossrefPubMedGoogle Scholar
  • 53 Krohn J, Hove VK. Iris cyst associated with topical administration of latanoprost. Am J Ophthalmol 1999; 127: 91-93
    PubMedGoogle Scholar
  • 54 Wand M, Shields BM. Cystoid macular edema in the era of ocular hypotensive lipids. Am J Ophthalmol 2002; 133: 393-397
    CrossrefPubMedGoogle Scholar
  • 55 Arranz-Marquez E, Teus MA. Prostanoids for the management of glaucoma. Expert Opin Drug Saf 2008; 7: 801-808
    CrossrefPubMedGoogle Scholar
  • 56 Schumer RA, Camras CB, Mandahl AK. Latanoprost and cystoid macular edema: is there a causal relation?. Curr Opin Ophthalmol 2000; 11: 94-100
    CrossrefPubMedGoogle Scholar
  • 57 Wand M, Gilbert CM, Liesegang TJ. Latanoprost and herpes simplex keratitis. Am J Ophthalmol 1999; 127: 602-604
    CrossrefPubMedGoogle Scholar
  • 58 Beam G, Reardon G, Zimmerman TJ. Association between ocular herpes simplex virus and topical ocular hypotensive therapy. J Glaucoma 2004; 13: 361-364
    CrossrefPubMedGoogle Scholar
  • 59 Tappeiner C, Perren B, Iliev ME et al. Orbitale Fettgewebsatrophie bei lokaler Bimatoprost-Therapie – Kann Bimatoprost einen Enophthalmus verursachen?. Klin Monatsbl Augenheilkd 2008; 225: 443-445
    Article in Thieme ConnectPubMedGoogle Scholar
  • 60 Stjernschantz JW, Albert DM, Hu DN et al. Mechanism and clinical significance of prostaglandin-induced iris pigmentation. Surv Ophthalmol 2002; 47: S162-S175
    CrossrefPubMedGoogle Scholar
  • 61 Costagliola C, Parmeggiani F, Sebastiani A. Assessing the cost-effectiveness of switching from a beta-blocker to latanoprost in the treatment of ocular hypertension. Expert Opin Pharmacother 2003; 4: 1775-1788
    CrossrefPubMedGoogle Scholar
  • 62 Orzalesi N, Rossetti L, Invernizzi T et al. Effect of timolol, latanoprost, and dorzolamide on circadian IOP in glaucoma or ocular hypertension. Invest Ophthalmol Vis Sci 2000; 41: 2566-2573
    PubMedGoogle Scholar